Advanced search
1 file | 318.85 KB Add to list

Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis

(2018) ANNALS OF THE RHEUMATIC DISEASES. 77(9). p.1311-1317
Author
Organization
Abstract
Objectives: To evaluate construct validity, interpretability, reliability and responsiveness as well as determination of cut-off points for good and poor health within the original English version and the 18 translations of the disease-specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI) in 23 countries worldwide in patients with spondyloarthritis (SpA). Methods: A representative sample of patients with SpA fulfilling the ASAS classification criteria for axial (axSpA) or peripheral SpA was used. The construct validity of the ASAS HI was tested using Spearman correlation with several standard health outcomes for axSpA. Test-retest reliability was assessed by intraclass correlation coefficients (ICCs) in patients with stable disease (interval 4-7 days). In patients who required an escalation of therapy because of high disease activity, responsiveness was tested after 2-24 weeks using standardised response mean (SRM). Results: Among the 1548 patients, 64.9% were men, with a mean (SD) age 42.0 (13.4) years. Construct validity ranged from low (age: 0.10) to high (Bath Ankylosing Spondylitis Functioning Index: 0.71). Internal consistency was high (Cronbach's alpha of 0.93). The reliability among 578 patients was good (ICC=0.87 (95% CI 0.84 to 0.89)). Responsiveness among 246 patients was moderate-large (SRM=-0.44 for non-steroidal anti-inflammatory drugs, -0.69 for conventional synthetic disease-modifying antirheumatic drug and -0.85 for tumour necrosis factor inhibitor). The smallest detectable change was 3.0. Values <= 5.0 have balanced specificity to distinguish good health as opposed to moderate health, and values >= a12.0 are specific to represent poor health as opposed to moderate health. Conclusions: The ASAS HI proved to be valid, reliable and responsive. It can be used to evaluate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of disease impact between populations is possible.
Keywords
SOCIETY CLASSIFICATION CRITERIA, ANKYLOSING-SPONDYLITIS, PHYSICIAN, DISCORDANCE, COHORT, ARTHRITIS, SELECTION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 318.85 KB

Citation

Please use this url to cite or link to this publication:

MLA
Kiltz, Uta et al. “Measurement Properties of the ASAS Health Index : Results of a Global Study in Patients with Axial and Peripheral Spondyloarthritis.” ANNALS OF THE RHEUMATIC DISEASES 77.9 (2018): 1311–1317. Print.
APA
Kiltz, U., van der Heijde, D., Boonen, A., Akkoc, N., Bautista-Molano, W., Burgos-Vargas, R., Wei, J. C.-C., et al. (2018). Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis. ANNALS OF THE RHEUMATIC DISEASES, 77(9), 1311–1317.
Chicago author-date
Kiltz, Uta, Desiree van der Heijde, Annelies Boonen, Nurullah Akkoc, Wilson Bautista-Molano, Ruben Burgos-Vargas, James Cheng-Chung Wei, et al. 2018. “Measurement Properties of the ASAS Health Index : Results of a Global Study in Patients with Axial and Peripheral Spondyloarthritis.” Annals of the Rheumatic Diseases 77 (9): 1311–1317.
Chicago author-date (all authors)
Kiltz, Uta, Desiree van der Heijde, Annelies Boonen, Nurullah Akkoc, Wilson Bautista-Molano, Ruben Burgos-Vargas, James Cheng-Chung Wei, Praveena Chiowchanwisawakit, Maxime Dougados, M Tuncay Duruoz, Bassel Kamal Elzorkany, Inna Gaydukova, Lianne S Gensler, Michele Gilio, Simeon Grazio, Jieruo Gu, Robert D Inman, Tae-Jong Kim, Victoria Navarro-Compan, Helena Marzo-Ortega, Salih Ozgocmen, Fernando Pimentel dos Santos, Michael Schirmer, Simon Stebbings, Filip Van den Bosch, Astrid van Tubergen, and Juergen Braun. 2018. “Measurement Properties of the ASAS Health Index : Results of a Global Study in Patients with Axial and Peripheral Spondyloarthritis.” Annals of the Rheumatic Diseases 77 (9): 1311–1317.
Vancouver
1.
Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, et al. Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis. ANNALS OF THE RHEUMATIC DISEASES. 2018;77(9):1311–7.
IEEE
[1]
U. Kiltz et al., “Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis,” ANNALS OF THE RHEUMATIC DISEASES, vol. 77, no. 9, pp. 1311–1317, 2018.
@article{8605299,
  abstract     = {Objectives: To evaluate construct validity, interpretability, reliability and responsiveness as well as determination of cut-off points for good and poor health within the original English version and the 18 translations of the disease-specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI) in 23 countries worldwide in patients with spondyloarthritis (SpA). 
Methods: A representative sample of patients with SpA fulfilling the ASAS classification criteria for axial (axSpA) or peripheral SpA was used. The construct validity of the ASAS HI was tested using Spearman correlation with several standard health outcomes for axSpA. Test-retest reliability was assessed by intraclass correlation coefficients (ICCs) in patients with stable disease (interval 4-7 days). In patients who required an escalation of therapy because of high disease activity, responsiveness was tested after 2-24 weeks using standardised response mean (SRM). 
Results: Among the 1548 patients, 64.9% were men, with a mean (SD) age 42.0 (13.4) years. Construct validity ranged from low (age: 0.10) to high (Bath Ankylosing Spondylitis Functioning Index: 0.71). Internal consistency was high (Cronbach's alpha of 0.93). The reliability among 578 patients was good (ICC=0.87 (95% CI 0.84 to 0.89)). Responsiveness among 246 patients was moderate-large (SRM=-0.44 for non-steroidal anti-inflammatory drugs, -0.69 for conventional synthetic disease-modifying antirheumatic drug and -0.85 for tumour necrosis factor inhibitor). The smallest detectable change was 3.0. Values <= 5.0 have balanced specificity to distinguish good health as opposed to moderate health, and values >= a12.0 are specific to represent poor health as opposed to moderate health. 
Conclusions: The ASAS HI proved to be valid, reliable and responsive. It can be used to evaluate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of disease impact between populations is possible.},
  author       = {Kiltz, Uta and van der Heijde, Desiree and Boonen, Annelies and Akkoc, Nurullah and Bautista-Molano, Wilson and Burgos-Vargas, Ruben and Wei, James Cheng-Chung and Chiowchanwisawakit, Praveena and Dougados, Maxime and Duruoz, M Tuncay and Elzorkany, Bassel Kamal and Gaydukova, Inna and Gensler, Lianne S and Gilio, Michele and Grazio, Simeon and Gu, Jieruo and Inman, Robert D and Kim, Tae-Jong and Navarro-Compan, Victoria and Marzo-Ortega, Helena and Ozgocmen, Salih and dos Santos, Fernando Pimentel and Schirmer, Michael and Stebbings, Simon and Van den Bosch, Filip and van Tubergen, Astrid and Braun, Juergen},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keywords     = {SOCIETY CLASSIFICATION CRITERIA,ANKYLOSING-SPONDYLITIS,PHYSICIAN,DISCORDANCE,COHORT,ARTHRITIS,SELECTION},
  language     = {eng},
  number       = {9},
  pages        = {1311--1317},
  title        = {Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2017-212076},
  volume       = {77},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: